Journal Home > Volume 7 , Issue 1
Journal of Neurorestoratology 2019, 7(1): 8-17 https://doi.org/10.26599/JNR.2019.9040003
Review Article | Open Access | Issue | Published: 22 March 2019

2018 Yearbook of Neurorestoratology

Show Author's Information Hongyun Huang1,2( ),  Hari Shanker Sharma3,  Lin Chen4,  Hooshang Saberi5,  Gengsheng Mao1
Institute of Neurorestoratology, Third Medical Center of General Hospital of PLA, Beijing, China
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing, China
Int. Exp. CNS Injury & Repair, Anesthesiology & Intensive Care Medicine, Department of Surgical Sciences, University Hospital, Uppsala University, Sweden
Department of Neurorestoratology, Tsinghua University Yuquan Hospital, Beijing, China
Brain and Spinal Research Center, Department of Neurosurgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
Keywords:
neurorestoratology, yearbook, pathogenesis, diseases and damage to the nervous system, neurorestorative mechanisms, neurorestorative therapies
Cite this article:
Huang H, Sharma HS, Chen L, et al. 2018 Yearbook of Neurorestoratology. Journal of Neurorestoratology, 2019, 7(1): 8-17. https://doi.org/10.26599/JNR.2019.9040003
Download citation
EndNote(RIS)
BibTeX

655

Views

35

Downloads

Citations

16

Crossref

18

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

The Neurorestoratology discipline is getting worldwide attention from the clinicians, basic scientists, students and policy makers alike. Accordingly, this year too, the discipline has made profound advances and great achievements for the benefit of the mankind. In this report, of the 2018 Neurorestoratology Yearbook, salient features of new developments are summarized. This Yearbook consists 3 key themes namely (i) the new findings on pathogenesis of neurological diseases or degeneration; (ii) the new mechanisms of neurorestorative aspects; and (iii) the achievements and progresses made in the clinical field of neurorestorative therapies. The new trend has emerged in clinical studies that are based on greater levels of evidence-based medical practices both in clinical therapies and clinical trials based on standard designs.


menu
Abstract
Full text
Outline
About this article

2018 Yearbook of Neurorestoratology

Show Author's information Hongyun Huang1,2( ), Hari Shanker Sharma3, Lin Chen4, Hooshang Saberi5, Gengsheng Mao1
Institute of Neurorestoratology, Third Medical Center of General Hospital of PLA, Beijing, China
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing, China
Int. Exp. CNS Injury & Repair, Anesthesiology & Intensive Care Medicine, Department of Surgical Sciences, University Hospital, Uppsala University, Sweden
Department of Neurorestoratology, Tsinghua University Yuquan Hospital, Beijing, China
Brain and Spinal Research Center, Department of Neurosurgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract

The Neurorestoratology discipline is getting worldwide attention from the clinicians, basic scientists, students and policy makers alike. Accordingly, this year too, the discipline has made profound advances and great achievements for the benefit of the mankind. In this report, of the 2018 Neurorestoratology Yearbook, salient features of new developments are summarized. This Yearbook consists 3 key themes namely (i) the new findings on pathogenesis of neurological diseases or degeneration; (ii) the new mechanisms of neurorestorative aspects; and (iii) the achievements and progresses made in the clinical field of neurorestorative therapies. The new trend has emerged in clinical studies that are based on greater levels of evidence-based medical practices both in clinical therapies and clinical trials based on standard designs.

Keywords: neurorestoratology, yearbook, pathogenesis, diseases and damage to the nervous system, neurorestorative mechanisms, neurorestorative therapies

References(71)

[1]
H Hampel, MM Mesulam, AC Cuello, et al. Revisiting the cholinergic hypothesis in Alzheimer’s disease: Emerging evidence from translational and clinical research. J Prev Alzheimers Dis. 2019, 6(1): 2-15.
Google Scholar
[2]
TE Cope, T Rittman, RJ Borchert, et al. Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2018, 141(2): 550-567.
DOI Google Scholar
[3]
N Musi, JM Valentine, KR Sickora, et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell. 2018, 17(6): e12840.
DOI Google Scholar
[4]
Y Wei, MR Shin, F Sesti. Oxidation of KCNB1 channels in the human brain and in mouse model of Alzheimer’s disease. Cell Death Dis. 2018, 9(8): 820.
DOI Google Scholar
[5]
A Gatt, A Ekonomou, A Somani, et al. Importance of proactive treatment of depression in Lewy body dementias: The impact on hippocampal neurogenesis and cognition in a post-mortem study. Dement Geriatr Cogn Disord. 2017, 44(5–6): 283-293.
DOI Google Scholar
[6]
ZX Hu, WN Song, XD Lu, et al. Peripheral T lymphocyte immunity and l-dopamine in patients with Parkinson’s disease. J Biol Regul Homeost Agents. 2018, 32(3): 687-691.
Google Scholar
[7]
AF Pardiñas, P Holmans, AJ Pocklington, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018, 50(3): 381-389.
Google Scholar
[8]
Y Shi, S Lin, KA Staats, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018, 24(3): 313-325.
DOI Google Scholar
[9]
SF Sorrells, MF Paredes, A Cebrian-Silla, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018, 555(7696): 377-381.
DOI Google Scholar
[10]
M Boldrini, CA Fulmore, AN Tartt, et al. Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell. 2018, 22(4): 589-599.
DOI Google Scholar
[11]
CH Nijboer, E Kooijman, CT van Velthoven, et al. Intranasal stem cell treatment as a novel therapy for subarachnoid hemorrhage. Stem Cells Dev. 2018, 27(5): 313-325.
DOI Google Scholar
[12]
T Kunath, A Natalwala, C Chan, et al. Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies? Eur J Neurosci. 2018, 49(4): 453-462.
DOI Google Scholar
[13]
JA da Silva, F Tecuapetla, V Paixão, et al. Dopamine neuron activity before action initiation gates and invigorates future movements. Nature. 2018, 554(7691): 244-248.
DOI Google Scholar
[14]
C Liu, L Kershberg, J Wang, et al. Dopamine secretion is mediated by sparse active zone-like release sites. Cell. 2018, 172(4): 706-718.
DOI Google Scholar
[15]
S Konermann, P Lotfy, NJ Brideau, et al. Transcriptome engineering with RNA-targeting Type VI-D CRISPR effectors. Cell. 2018, 173(3): 665-676.e14.
DOI Google Scholar
[16]
M Pignatelli, TJ Ryan, DS Roy, et al. Engram cell excitability state determines the efficacy of memory retrieval. Neuron. 2019, 101(2): 274-284.e5.
DOI Google Scholar
[17]
TJ Bussian, A Aziz, CF Meyer, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018, 562(7728): 578-582.
DOI Google Scholar
[18]
TA Bedrosian, C Quayle, N Novaresi, et al. Early life experience drives structural variation of neural genomes in mice. Science. 2018, 359(6382): 1395-1399.
DOI Google Scholar
[19]
AD Levi, KD Anderson, DO Okonkwo, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2018.
DOI Google Scholar
[20]
LH Guadalajara, AM León, CJ Vaquero, et al. Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy. J Surg Case Rep. 2018, 2018(11): rjy300.
DOI Google Scholar
[21]
J Vaquero, M Zurita, MA Rico, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy. 2018, 20(6): 806-819.
Google Scholar
[22]
J Vaquero, M Zurita, MA Rico, et al. Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia. Cytotherapy. 2018, 20(6): 796-805.
DOI Google Scholar
[23]
J Vaquero, M Zurita, MA Rico, et al. Intrathecal administration of autologous bone marrow stromal cells improves neuropathic pain in patients with spinal cord injury. Neurosci Lett. 2018, 670: 14-18.
DOI Google Scholar
[24]
AJ Santamaría, FD Benavides, DL DiFede, et al. Clinical and neurophysiological changes after targeted intrathecal injections of bone marrow stem cells in a C3 tetraplegic subject. J Neurotrauma. 2018, 36(3).
DOI Google Scholar
[25]
GA Moviglia, MTM Brandolino, D Couto, et al. Local immunomodulation and muscle progenitor cells induce recovery in atrophied muscles in spinal cord injury patients. J Neurorestoratology. 2018, 6(1): 136-145.
DOI Google Scholar
[26]
S Al Kandari, L Prasad, M Al Kandari, et al. Cell transplantation and clinical reality: Kuwait experience in persons with spinal cord injury. Spinal Cord. 2018, 56(7): 674-679.
DOI Google Scholar
[27]
NT Liem, VD Chinh, NT Thinh, et al. Improved bowel function in patients with spina bifida after bone marrow- derived mononuclear cell transplantation: A report of 2 cases. Am J Case Rep. 2018, 19: 1010-1018.
DOI Google Scholar
[28]
PH Sung, HS Lin, WC Lin, et al. Intra-carotid arterial transfusion of autologous circulatory derived CD34+ cells for old ischemic stroke patients - a phase I clinical trial to evaluate safety and tolerability. Am J Transl Res. 2018, 10(9): 2975-2989.
Google Scholar
[29]
SI Savitz, D Yavagal, G Rappard, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). Circulation. 2018, 139(2): 192-205.
DOI Google Scholar
[30]
DT Laskowitz, ER Bennett, RJ Durham, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: Clinical outcomes from a phase I safety study. Stem Cells Transl Med. 2018, 7(7): 521-529.
DOI Google Scholar
[31]
CG van Horne, JE Quintero, JT Slevin, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s diseaseduring deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018, 129(6): 1550-1561.
DOI Google Scholar
[32]
TL Nguyen, HP Nguyen, TK Nguyen. The effects of bone marrow mononuclear cell transplantation on the quality of life of children with cerebral palsy. Health Qual Life Outcomes. 2018, 16(1): 164.
DOI Google Scholar
[33]
C Elena, S Ekaterina, K Marina, et al. Monocyte-derived macrophages for treatment of cerebral palsy: A study of 57 cases. J Neurorestoratology. 2018, 6(1): 41-47.
DOI Google Scholar
[34]
L da Cruz, K Fynes, O Georgiadis, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018, 36(4): 328-337.
DOI Google Scholar
[35]
G Mao, Y Wang, X Guo, et al. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: Design of a multicenter randomized double-blinded placebo-controlled clinical study. J Neurorestoratology. 2018, 6(1): 74-80.
Google Scholar
[36]
TG Phan, H Ma, R Lim, et al. Phase 1 trial of amnion cell therapy for ischemic stroke. Front Neurol. 2018, 9: 198.
DOI Google Scholar
[37]
L Deng, Q Peng, H Wang, et al. Intrathecal injection of allogenic bone marrow-derived mesenchymal stromal cells in treatment of patients with severe ischemic stroke: Study protocol for a randomized controlled observer-blinded trial. Transl Stroke Res. 2018: 1-8.
DOI Google Scholar
[38]
T Osanai, K Houkin, S Uchiyama, et al. Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design. Int J Stroke. 2018, 13(4): 444-448.
DOI Google Scholar
[39]
I Garitaonandia, R Gonzalez, G Sherman, et al. Novel approach to stem cell therapy in Parkinson’s disease. Stem Cells Dev. 2018, 27(14): 951-957.
DOI Google Scholar
[40]
JF Loring. Autologous induced pluripotent stem cell-derived neurons to treat Parkinson’s disease.Stem Cells Dev. 2018, 27(14): 958-959.
DOI Google Scholar
[41]
N Cichoń, M Bijak, P Czarny, et al. Increase in blood levels of growth factors involved in the neuroplasticity process by using an extremely low frequency electromagnetic field in post-stroke patients. Front Aging Neurosci. 2018, 10: 294.
DOI Google Scholar
[42]
CA Angeli, M Boakye, RA Morton, et al. Recovery of over- ground walking after chronic motor complete spinal cord injury. N Engl J Med. 2018, 379(13): 1244-1250.
DOI Google Scholar
[43]
ML Gill, PJ Grahn, JS Calvert, et al. Neuromodulation of lumbosacral spinal networks enables independent stepping after complete paraplegia. Nat Med. 2018, 24(11): 1677-1682.
DOI Google Scholar
[44]
AN Herrity, CS Williams, CA Angeli, et al. Lumbosacral spinal cord epidural stimulation improves voiding function after human spinal cord injury. Sci Rep. 2018, 8(1): 8688.
DOI Google Scholar
[45]
DGL Terson de Paleville, SJ Harkema, CA Angeli. Epidural stimulation with locomotor training improves body composition in individuals with cervical or upper thoracic motor complete spinal cord injury: A series of case studies. J Spinal Cord Med. 2018, 42(1): 1-7.
DOI Google Scholar
[46]
FB Wagner, JB Mignardot, CG Le Goff-Mignardot, et al. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018, 563: 65-71.
DOI Google Scholar
[47]
SJ Harkema, S Wang, CA Angeli, et al. Normalization of blood pressure with spinal cord epidural stimulation after severe spinal cord injury. Front Hum Neurosci. 2018, 12: 83.
DOI Google Scholar
[48]
SC Aslan, BE Legg Ditterline, MC Park, et al. Epidural spinal cord stimulation of lumbosacral networks modulates arterial blood pressure in individuals with spinal cord injury- induced cardiovascular deficits. Front Physiol. 2018, 9: 565.
DOI Google Scholar
[49]
R Poiani, AL Zaninotto, AMC Carneiro, et al. Photobiomodulation using low-level laser therapy (LLLT) for patients with chronic traumatic brain injury: A randomized controlled trial study protocol. Trials. 2018, 19(1): 17.
DOI Google Scholar
[50]
JGRPD Santos, ALC Zaninotto, RA Zângaro, et al. Effects of transcranial LED therapy on the cognitive rehabilitation for diffuse axonal injury due to severe acute traumatic brain injury: Study protocol for a randomized controlled trial. Trials. 2018, 19(1): 249.
DOI Google Scholar
[51]
T da Silva, FC da Silva, AO Gomes, et al. Effect of photobiomodulation treatment in the sublingual, radial artery region, and along the spinal column in individuals with multiple sclerosis: Protocol for a randomized, controlled, double-blind, clinical trial. Medicine (Baltimore). 2018, 97(19):e0627.
DOI Google Scholar
[52]
S Falci, C Indeck, D Barnkow. Spinal cord injury below- level neuropathic pain relief with dorsal root entry zone microcoagulation performed caudal to level of complete spinal cord transection.J Neurosurg Spine. 2018, 28(6): 612-620.
DOI Google Scholar
[53]
H Huang, Z Al Zoubi. A brief introduction to the Special Issue on clinical treatment of spinal cord injury. J Neurorestoratology. 2018, 6: 134-135.
DOI Google Scholar
[54]
CC Ko, TH Tu, JC Wu, et al. Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor. Sci Rep. 2018, 8(1): 12691.
DOI Google Scholar
[55]
N Derakhshanrad, H Saberi, MS Yekaninejad, et al. Subcutaneous granulocyte colony-stimulating factor administration for subacute traumatic spinal cord injuries, report of neurological and functional outcomes: A double-blind randomized controlled clinical trial. J Neurosurg Spine. 2018: 1-12.
DOI Google Scholar
[56]
N Derakhshanrad, H Saberi, MS Yekaninejad, et al. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double- blind randomized controlled clinical trial.J Neurosurg Spine. 2018, 29(1): 97-107.
DOI Google Scholar
[57]
CM McDonald, B Wong, KM Flanigan, et al. Placebo- controlled phase 2 trial of drisapersen for Duchenne Muscular Dystrophy. Ann Clin Transl Neurol. 2018, 5(8): 913-926.
DOI Google Scholar
[58]
F Panza, D Seripa, M Lozupone, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opin Biol Ther. 2018, 18(1): 25-35.
DOI Google Scholar
[59]
KA Strauss, VJ Carson, KW Brigatti, et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy. J Pediatr Orthop. 2018, 38(10): e610-e617.
DOI Google Scholar
[60]
O Eckstein, CL McAtee, J Greenberg, et al. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018: 1-7.
DOI Google Scholar
[61]
K Kucher, D Johns, D Maier, et al. First-in-man intrathecal application of neurite growth-promoting Anti-Nogo-A antibodies in acute spinal cord injury. Neurorehab Neural Re. 2018, 32(6–7): 578-589.
DOI Google Scholar
[62]
CH Hubscher, AN Herrity, CS Williams, et al. Improvements in bladder, bowel and sexual outcomes following task-specific locomotor training in human spinal cord injury. PLoS One. 2018, 13(1): e0190998.
DOI Google Scholar
[63]
BM Sandroff, RW Motl, M Bamman, et al. Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis. BMJ Open. 2018, 8(12): e023231.
DOI Google Scholar
[64]
C Trento, ME Bernardo, A Nagler, S Kuçi, et al. Manufacturing mesenchymal stromal cells for the treatment of graft-versus- host disease: A survey among centers affiliated with the European society for blood and marrow transplantation. Biol Blood Marrow Tr. 2018, 24(11): 2365-2370.
DOI Google Scholar
[65]
Q Ao, J Xiao, Y Yu, et al. Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017). J Neurorestoratology. 2018, 6: 11-15.
DOI Google Scholar
[66]
S Feng, J Xiao, F Han, et al. Neurorestorative clinical application standards for the culture and quality control of neural progenitor/precursor cells (version 2017). J Neurorestoratology. 2018, 6: 115-119.
DOI Google Scholar
[67]
EM Horwitz, K Le Blanc, M Dominici, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005, 7(5): 393-395.
DOI Google Scholar
[68]
M Dominici, K Le Blanc, I Mueller, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8(4): 315-317.
DOI Google Scholar
[69]
J Galipeau, M Krampera, J Barrett, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016, 18(2): 151-159.
DOI Google Scholar
[70]
H Huang, W Young, L Chen, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2017). Cell Transplant. 2018, 27(2): 310-324.
Google Scholar
[71]
M Bikson, B Paneri, A Mourdoukoutas, et al. Limited output transcranial electrical stimulation (LOTES-2017): Engineering principles, regulatory statutes, and industry standards for wellness, over-the-counter, or prescription devices with low risk. Brain Stimul. 2018, 11(1): 134-157.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 05 January 2019
Revised: 17 January 2019
Accepted: 22 January 2019
Published: 22 March 2019
Issue date: March 2019

Copyright

© The authors 2019

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return